Express News | G1 Therapeutics Added To Russell 2000 And 3000 Indexes, Effective At Open Jul. 1

BenzingaJul 1 08:11 ET

G1 Therapeutics Added to the Russell 2000 and 3000 Indexes

RESEARCH TRIANGLE PARK, N.C., July 01, 2024 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (NASDAQ:GTHX), a commercial-stage oncology company, today announced that the Company has been added to the broad-market Russell

GlobeNewswireJul 1 08:00 ET

TD Cowen Maintains G1 Therapeutics(GTHX.US) With Buy Rating

TD Cowen analyst Joseph Thome maintains $G1 Therapeutics(GTHX.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 40.2% and a total average return of -9.5% over the pa

Moomoo NewsJun 25 13:32 ET · Ratings

Ball To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.JP Morgan c

BenzingaJun 25 07:27 ET

G1 Therapeutics Drops as Breast Cancer Therapy Fails in Late-stage Trial

Seeking AlphaJun 25 06:59 ET

Needham Maintains G1 Therapeutics(GTHX.US) With Buy Rating, Cuts Target Price to $6

Needham analyst Gil Blum maintains $G1 Therapeutics(GTHX.US)$ with a buy rating, and adjusts the target price from $12 to $6.According to TipRanks data, the analyst has a success rate of 39.7% and a t

Moomoo NewsJun 25 06:31 ET · Ratings